Frank AL, et al. - Researchers used claims data of 14,453 cases with Idiopathic Interstitial Pneumonia (IIP) or 9106 cases with sarcoidosis in order to evaluate the cost impact of chronic obstructive pulmonary disease (COPD), diabetes, coronary artery disease, depression, gastro-esophageal reflux disease, pulmonary hypertension (PH), obstructive sleep apnoea syndrome (OSAS) and lung cancer on costs of care of interstitial lung disease (ILD) cases within first year after diagnosis. In the pooled cohort, in IIP and in sarcoidosis, the total mean annual per capita costs were €11 131, €12 111, and €8793, respectively, each with a 1/3 share of ILD-associated cost. A significant cost-driving influence of most comorbidities was evident, which was most pronounced for lung cancer in total and for PH in ILD-associated costs. A more strong impact of lung-associated comorbidities COPD, PH, OSAS on ILD-associated than total costs was seen. Overall, the already substantial costs of care in ILDs were increased due to the presence of comorbidities.